Tests vonaprument long term in people with dry macular degeneration
Checks long-term safety of eye injections of vonaprument in adults with geographic atrophy.
Plain-language title generated from the registry record
Registry title: An Open-label Extension Study of the Long-Term Safety of Vonaprument (ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)
Key facts
- Where
- Asheville, Eugene, Hagerstown, Sarasota, Springfield, and St. Petersburg, United StatesSee the 7 sites
- Phase
- Phase 3
Where in United States
- Asheville Eye Associates - Retina DivisionAsheville, United StatesNo longer taking part
- Verum Research, LLCEugene, United StatesNo longer taking part
- Cumberland Valley Retina ConsultantsHagerstown, United StatesNo longer taking part
- Mid Atlantic Retina SpecialistsHagerstown, United StatesNo longer taking part
- Retina Group of FloridaSarasota, United StatesNo longer taking part
- Retina Research Institute at New England Retina ConsultantsSpringfield, United StatesNo longer taking part
- Retina Vitreous Associates of FloridaSt. Petersburg, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Annexon, Inc.
- Trial code
- NCT07807969EU 2026-527023-96-00
- Record updated
- 8 September 2026
- Original description
The primary purpose of the study is to assess the long term safety of intravitreal (IVT) injections of vonaprument.Read full original descriptionShow less
A Multicenter, Open-Label Extension Study of the Long-Term Safety of Vonaprument (ANX007) Administered by Intravitreal Injection in Participants With Dry Age-Related Macular Degeneration With Geographic Atrophy
The primary purpose of the study is to assess the long term safety of intravitreal (IVT) injections of vonaprument.
Inclusion: Participants with a diagnosis of dry AMD with GA who completed the Phase 3 ARCHER II study (NCT06510816) and who had not permanently ceased receiving the assigned masked treatment (IVT or Sham administration) at/before the ARCHER II Month 24 Visit.
Exclusion: Any event or condition arising during the ARCHER II study that would put the participant in danger or lead to undue harm by participating in this OLE study.